Veritas Pharma Stock Net Asset
| VRTHFDelisted Stock | USD 0 0.00 0.00% |
Fundamental analysis of Veritas Pharma allows traders to better anticipate movements in Veritas Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Veritas |
Veritas Pharma Company Net Asset Analysis
Veritas Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Veritas Pharma Net Asset | 730 |
Most of Veritas Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veritas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Veritas Pharma has a Net Asset of 730. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.
Veritas Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veritas Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Veritas Pharma could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics of similar companies.Veritas Pharma is currently under evaluation in net asset category among its peers.
Veritas Fundamentals
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Shares Owned By Insiders | 27.34 % | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| Gross Profit | (112.96 K) | |||
| EBITDA | (491.67 K) | |||
| Net Income | (2.29 M) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.64 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | -0.0588 | |||
| Market Capitalization | 1.59 M | |||
| Total Asset | 730 | |||
| Net Asset | 730 |
About Veritas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veritas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veritas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veritas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Veritas Pink Sheet
If you are still planning to invest in Veritas Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Veritas Pharma's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |